MRGN Advisors capitalizes on direct operational experience in healthcare investment and operations management to deliver innovation, business development and partnering, funding and access strategies.
Illustrative assignments performed recently:
Definition of strategy and company reorganization to ensure consistency between strategic priorities and the external environment and to optimize commercial organization towards upcoming product launches.
Execution of a series A round of financing.
Due to the long company history and to the slow development pac e,
review of the available preclinical data and of the IP situation to form the backbone of the value story. Analysis of the competitive landscape and of the proposed positioning of the company assets. Fine-tuning of the investor pitch documents and execution of multiple investor presentations.
Recommendations to the chairman and to selected shareholders for
organizational and management changes in order to enhance the odds of success of the fund raising.
Seeking expertise and input into the Company’s strategic marketing plans for its novel pharmaceutical products in development in the field of allergy immunotherapy.
Preparation of a comprehensive business plan and value curve analysis.
Piloting of a qualitative and quantitative market research in the USA
and in major targeted European countries. Preparation of board
recommendations. Execution of investor pre-pitches in anticipation of
planned series B and of business development presentations to large life science companies.
Seeking consulting services in the fields of portfolio strategy and business development for its disruptive manufacturing solutions for viral vaccines and biologics.
Analysis of the potential market (companies positioned in the fields of vaccines and biologics) and of the universe of targets.
Support to the preparation of pitch documents, definition and execution of a business development plan spanning Europe, Asia and Latin America.
Execution of investor pitches in support to series A financing. Support to the proposition document towards securing financing from the Global Health Investment Fund (EUR 22.5m)
Participation to Executive Committee seminars to review the strategic orientations and their implementation.
